Compositions and methods for treating pain, inflammation, infection, malaria, and sepsis
AssigneeDuke University
InventorsRu-Rong Ji, Sangsu Bang, Zhen-Zhong Xu
Life of this patent
Estimating the term…
Abstract
Disclosed herein are methods and compositions for treating a disease or disorder in a subject in need thereof. The methods may include administering to the subject a therapeutically effective amount of a GPR37 agonist. The disease or disorder may be selected from inflammation, inflammatory pain, chronic pain, viral infection, bacterial infection, malaria, sepsis, or a combination thereof.
Claims20
A method of treating a disease or disorder in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of a GPR37 agonist, wherein the disease or disorder is selected from inflammation, inflammatory pain, chronic pain, viral infection, bacterial infection, malaria, sepsis, or a combination thereof.
A method of reducing the duration of inflammation in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of a GPR37 agonist.
A method of increasing phagocytosis of macrophages in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of a GPR37 agonist.
The method of any one of the above claims, wherein the GPR37 agonist comprises a polynucleotide, polypeptide, small molecule, carbohydrate, lipid, or a combination thereof.
The method of any one of the above claims, wherein the GPR37 agonist is selected from NPD1, TX-14, artisunate, apigenin, honokiol, any derivatives, esters, or salts thereof, or a combination thereof.
The method of any one of the above claims, wherein intracellular calcium influx is increased.
The method of any one of the above claims, wherein expression of pro-inflammatory cytokines in macrophages is decreased.
The method of any one of the above claims, wherein expression of anti-inflammatory cytokines in macrophages is increased.
A pharmaceutical composition comprising a GPR37 agonist.
Dependencies are inferred from the claim text.